GlassScriptPhysician profile
Mary A Depaz
NPI 1700846664
$9,765.89
in general payments reported to CMS, 2019-2025
58 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $421 · 2021: $857 · 2022: $1,839 · 2023: $1,688 · 2024: $2,197 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,677.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,027.59 | 2019-2025 | Erleada, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $937.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $791.21 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Abbvie INC. | $689.49 | 2021-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $640.27 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $556.47 | 2019-2023 | Imbruvica |
| Lilly USA, LLC | $470.12 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $437.67 | 2019-2025 | |
| Daiichi Sankyo INC. | $393.87 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $258.72 | 2019-2023 | Tukysa |
| Incyte Corporation | $254.31 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $237.35 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Astellas Pharma US INC | $229.03 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $216.30 | 2019-2025 | |
| Amgen INC. | $207.88 | 2019-2023 | Vectibix, Nplate, Lumakras |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Depaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.